Citius Pharma subsidiary Citius Oncology says new LYMPHIR institutional accounts jump 78% Q/Q
Reuters2026/08/05 13:27- Citius Pharma’s majority-owned unit Citius Oncology reported faster early uptake for LYMPHIR in cutaneous T-cell lymphoma.
- New institutional accounts ordering LYMPHIR rose 78% quarter over quarter in the June 30, 2026 quarter; total institutional vial orders increased 31%.
- LYMPHIR reached 42 institutions; Citius Oncology expects more than 20 additional institutions in the current quarter.
- Near-universal payer coverage cited; initial CTCL market opportunity for LYMPHIR pegged at more than USD 400 million.
- Revenue recognition tied to wholesale orders placed and filled; wholesalers have started reordering as demand increases.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The higher the yen rises, the more retail investors short! 3.61 trillion yen short bets defy the trend, triggering a short squeeze warning
Even though the yen has reached its highest level in months, Japanese retail investors continue to bet that its sharp rebound will come to an end, and are consistently increasing their short positions.
EUR/USD Price Forecast: Bullish bias remains above 1.1600 ahead of ECB and US inflation
Abraxas Capital hedges $353M ETH short with $32M buy – Here’s why
Pons propels Robinhood Chain fees to record $6 million in daily fees as DEX volume doubles
Crypto prices
More
